Tarsus Pharmaceuticals/$TARS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Tarsus Pharmaceuticals
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
- Ticker
- $TARS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 370
- Headquarters
- Irvine, United States
- Website
- tarsusrx.com
TARS Metrics
BasicAdvanced
$3B
-
-$1.08
0.54
-
Price and volume
Market cap
$3B
Beta
0.54
52-week high
$91.53
52-week low
$53.89
Average daily volume
930K
Financial strength
Current ratio
3.198
Quick ratio
3.118
Long term debt to equity
0.256
Total debt to equity
0.256
Interest coverage (TTM)
-5.54%
Profitability
EBITDA (TTM)
-46.195
Gross margin (TTM)
82.67%
Net profit margin (TTM)
-7.67%
Operating margin (TTM)
-8.00%
Effective tax rate (TTM)
-18.11%
Revenue per employee (TTM)
$1,640,000
Management effectiveness
Return on assets (TTM)
-5.48%
Return on equity (TTM)
-13.68%
Valuation
Price to revenue (TTM)
4.82
Price to book
8.49
Price to tangible book (TTM)
8.67
Price to free cash flow (TTM)
52.189
Free cash flow yield (TTM)
1.92%
Free cash flow per share (TTM)
1.304
Growth
Revenue change (TTM)
105.17%
Earnings per share change (TTM)
-53.20%
3-year revenue growth (CAGR)
264.70%
3-year earnings per share growth (CAGR)
-31.74%
What the Analysts think about TARS
Analyst ratings (Buy, Hold, Sell) for Tarsus Pharmaceuticals stock.
Analyst projections of the future price of Tarsus Pharmaceuticals stock.
Bulls say / Bears say
XDEMVY’s sales momentum is strong: second-quarter net sales rose 69% year on year to $173.9 million, and Tarsus raised its 2026 sales guidance to $685–705 million. (GlobeNewswire)
Prescribing and patient awareness are broadening, which could support further growth: the number of eye-care professionals prescribing XDEMVY at least five times a week doubled year on year, while unaided awareness of Demodex blepharitis reached about 30%, from 2% before the campaign. (GlobeNewswire)
Tarsus has broadened its pipeline beyond XDEMVY by acquiring ALK-001, a Stargardt disease drug now in Phase 3 development. The asset could add a second growth driver if trials succeed. (GlobeNewswire)
The business remains heavily reliant on XDEMVY, and its sales fell sequentially in the first quarter of 2026 for the first time since launch. That makes continued growth vulnerable to uneven demand for its single commercial product. (Last10K, Seeking Alpha)
The Alkeus acquisition requires $270 million in upfront cash and nearly 2.9 million Tarsus shares, with up to $350 million more in milestone payments. Tarsus also raised $125 million through a share-and-warrant financing, adding dilution as it funds expansion. (StockTitan, GlobeNewswire)
The pipeline is not a near-term earnings backstop: Phase 2 results for TP-04 and TP-05 are expected in the first half of 2027, while Phase 3 results for ALK-001 are expected in 2029. Delays or disappointing trial results could leave XDEMVY carrying the growth story for longer. (GlobeNewswire, GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2026.
TARS Financial Performance
Revenues and expenses
TARS Earnings Performance
Company profitability
Upcoming events
No upcoming events
TARS News
AllArticlesVideos
Funds containing TARS
Fund name | Fund size | $TARS weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.22% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.22% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.10% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.10% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.